A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

To join this study, you need to be at least 18 years old and have advanced non-small cell lung cancer that has been confirmed by a doctor. Your cancer must also have a specific gene fault called an 'EGFR Exon 20 insertion' or another less common EGFR gene change. This will be checked by a lab test.

Depending on your specific situation, there are different groups within the study. For example, some groups are for people who have already had certain treatments for their lung cancer, while others are for those who haven't. If your cancer has spread to your brain, you might still be able to join if your condition is stable and you've had treatment for it.

It's very important to discuss your full medical history with the study team. They will carefully check if this study is suitable and safe for you to join based on all the detailed rules. They will also make sure you understand everything before you make a decision.

Taking part in this study would involve regular hospital or clinic visits for check-ups, scans, and blood tests to see how you are responding to the medication and to monitor for any side effects. You would receive the study drug, zipalertinib, which is taken as a pill. The exact schedule for taking the medication and how often you'd need to visit will be explained by the study team.

Some parts of the study might also involve specific tests to see how the drug interacts with other medicines or to find the best dose. The total length of your participation would depend on your response to the treatment and the specific study group you are in, but it could involve ongoing treatment and follow-up appointments for a significant period. You'll have close medical supervision throughout.